Use of akkermansia for treating metabolic disorders

Abstract

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

1 - 17 . (canceled) 
     
     
         18 . A method for treating a metabolic disorder in a subject in need thereof, the method comprising orally administering a composition comprising a therapeutically effective amount of bacteria consisting essentially of substantially purified  Akkermansia  to the subject wherein the substantially purified  Akkermansia  comprises at least 50% of a strain of  Akkermansia.    
     
     
         19 . The method according to  claim 18 , wherein said metabolic disorder is obesity. 
     
     
         20 . The method according to  claim 18 , wherein said metabolic disorder is selected from the group consisting of metabolic syndrome, insulin-deficiency, insulin-resistance related disorder, diabetes mellitus, glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, stroke, non-alcoholic fatty liver disease, dyslipidemia, high cholesterol, elevated triglycerides, sleep apnea, osteoarthritis, neurodegenerative disorder, inflammatory disorder, immune disorder, atherogenic dyslipidemia, and heart disease. 
     
     
         21 . The method according to  claim 18 , wherein viable cells of the  Akkermansia  are administered to the subject. 
     
     
         22 . The method according to  claim 18 , wherein the composition is administered one or more times. 
     
     
         23 . The method according to  claim 18 , wherein the composition is administered to the subject at least three times a week. 
     
     
         24 . The method according to  claim 18 , wherein the  Akkermansia  is co-administered with another probiotic strain and/or with one or more prebiotics. 
     
     
         25 . The method according to  claim 24 , wherein the  Akkermansia  is co-administered with another probiotic strain. 
     
     
         26 . The method according to  claim 24 , wherein the  Akkermansia  is co-administered with one or more prebiotics. 
     
     
         27 . The method according to  claim 18 , wherein said metabolic disorder is selected from the group consisting of obesity, insulin-deficiency, and insulin-resistance related disorders. 
     
     
         28 . The method according to  claim 18 , wherein the bacteria consist essentially of  Akkermansia.    
     
     
         29 . The method according to  claim 18 , wherein the composition comprises a coating. 
     
     
         30 . The method according to  claim 18 , wherein the  Akkermansia  is non-viable. 
     
     
         31 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 60% of a strain of  Akkermansia.    
     
     
         32 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 70% of a strain of  Akkermansia.    
     
     
         33 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 80% of a strain of  Akkermansia.    
     
     
         34 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 85% of a strain of  Akkermansia.    
     
     
         35 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 90% of a strain of  Akkermansia.    
     
     
         36 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 95% of a strain of  Akkermansia.    
     
     
         37 . The method according to  claim 18 , wherein the substantially purified  Akkermansia  comprises at least about 99% or more of a strain of  Akkermansia.